KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Other Non Operating Income (2017 - 2026)

West Pharmaceutical Services has reported Other Non Operating Income over the past 12 years, most recently at -$200000.0 for Q1 2026.

  • Quarterly Other Non Operating Income changed 0.0% to -$200000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.0 million through Mar 2026, up 16.67% year-over-year, with the annual reading at -$1.0 million for FY2025, 0.0% changed from the prior year.
  • Other Non Operating Income was -$200000.0 for Q1 2026 at West Pharmaceutical Services, up from -$400000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $3.8 million in Q3 2023 and troughed at -$49.3 million in Q3 2022.
  • The 5-year median for Other Non Operating Income is -$200000.0 (2025), against an average of -$3.9 million.
  • Biggest five-year swings in Other Non Operating Income: tumbled 4581.82% in 2022 and later surged 107.71% in 2023.
  • Tracing WST's Other Non Operating Income over 5 years: stood at -$2.2 million in 2022, then soared by 59.09% to -$900000.0 in 2023, then skyrocketed by 66.67% to -$300000.0 in 2024, then plummeted by 33.33% to -$400000.0 in 2025, then surged by 50.0% to -$200000.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$200000.0, -$400000.0, and -$200000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.